



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[\[Sign In\]](#) [\[Regis\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display Abstract

Show 20

Sort by

Send to

About Entrez

Text Version

All: 1 Review: 0

Entrez PubMed

Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources

Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: [Clin Immunol.](#) 2003 Aug;108(2):103-10.

[Related Articles, Links](#)

ELSEVIER
FULL-TEXT ARTICLE

Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB x NZW) F1 mice.

[Chen SY](#), [Chen YC](#), [Wang JK](#), [Hsu HP](#), [Ho PS](#), [Chen YC](#), [Sytwu HK](#).

Institute of Undersea and Hyperbaric Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.

The effects of hyperbaric oxygen (HBO(2)) therapy on the immune system are reported including potential changes to the CD4/CD8 ratio and a decreased proliferation of lymphocytes during exposure. The immunosuppressive effect of HBO(2) had been suggested to be applicable for the treatment of certain autoimmune diseases. (NZB x NZW) F1 hybrid mice, the unique lupus-prone mice, have been used for elucidating the pathogenesis of SLE. To investigate the effect of HBO(2) on NZB/W F1 lupus-prone mice, 32 female mice were divided into four groups. Three groups of mice were treated with HBO(2) (2.5 atm abs (ATA) for 90 min daily over 2 weeks) starting at (A) 3 months, (B) 6 months, or (C) 8 months of age, while the remaining group (D) served as control. Animals were followed until 11 months of age. Experimental parameters included life span, proteinuria, peripheral lymphocytes, anti-dsDNA antibody titers, and renal histopathology. HBO(2) treatment resulted in increased survival, decreased proteinuria, alterations in lymphocyte-subset redistribution, reduced anti-dsDNA antibody titers, and amelioration of immune-complex deposition in groups A and B. Our data demonstrated that HBO(2) therapy attenuated disease severity in NZB/W F1 mice. HBO(2) treatment may be of use in the clinical treatment of lupus patients and would benefit from further study.

Publication Types:

- [Comparative Study](#)
- [Research Support, Non-U.S. Gov't](#)

PMID: 12921756 [PubMed - indexed for MEDLINE]